Vimentin-IN-1

Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin ( VIM ), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and multinucleation in transformed VIM-expressing mesenchymal cancer cells. Vimentin-IN-1 shows better oral bioavailability and pharmacokinetic profiles than FiVe1 In Vitro Vimentin-IN-1 (compound 4e) (0-10 mM; 72 h) inhibits a marked improvement in potency with an IC 50 value of 44 nM against HT-1080 fibrosarcoma, better than than FiVe1 (IC 50 =1.6 μM, HT-1080). Vimentin-IN-1 (0.1 μM; 24 h) induces phosphorylation of VIM at Ser56. Vimentin-IN-1 (100 μM; sampled at 0, 5, 15, 30, 45, and 60 min) exhibits poor stability with 0.0% remaining after 60 min of incubation in mouse liver microsome. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HT-1080, RD, and MCF-7 cells Concentration: 0-10 mM Incubation Time: 72 hours Result: Inhibited HT-1080, RD, and MCF-7 cells with IC 50 s of 44 nM, 61 nM, and 49 nM, respectively. In Vivo Vimentin-IN-1 (compound 4e) (10 mg/kg; p.o.; single dose) shows better oral pharmacokinetic properties than Five1 . Pharmacokinetic properties of Vimentin-IN-1 in mice Route Dose (mg/kg) AUC 0-last (ng·h/mL) AUC 0-inf (ng·h/mL) T 1/2 (h) T max (h) T last (h) C max (ng/mL) 4e PO 10 371.33 534.33 4.68 0.67 8 154.67 4e IP 1 208.33 211.33 0.59 0.25 4 197.00 Five1 PO 25 309.78 339.21 4.57 0.5 18 110.43 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:vimentin (VIM)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet